Geneos Wealth Management’s Celldex Therapeutics CLDX Stock Holding History

Geneos Wealth Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,333	Closed	-$51K	–	2785
2021 Q4	$51K	Hold	1,333	–	–	﹤0.01%	1463
2021 Q3	$74K	Hold	1,333	–	–	﹤0.01%	1294
2021 Q2	$45K	Hold	1,333	–	–	﹤0.01%	1529
2021 Q1	$40K	Hold	1,333	–	–	﹤0.01%	1738
2020 Q4	$27K	Hold	1,333	–	–	﹤0.01%	1743
2020 Q3	$17K	Hold	1,333	–	–	﹤0.01%	1721
2020 Q2	$16K	Hold	1,333	–	–	﹤0.01%	1714
2020 Q1	$2K	Hold	1,333	–	–	﹤0.01%	2238
2019 Q4	$2K	Hold	1,333	–	–	﹤0.01%	2358
2019 Q3	$2K	Hold	1,333	–	–	﹤0.01%	2288
2019 Q2	$3K	Hold	1,333	–	–	﹤0.01%	2208
2019 Q1	$6K	Buy	+1,333	New	+$7.01K	﹤0.01%	1979

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Geneos Wealth Management's CLDX Position: Q1 2022 in Review

Geneos Wealth Management sold out of Celldex Therapeutics (CLDX) in Q1 2022, closing a stake of 1,333 shares — an estimated $51K sold.

Geneos Wealth Management first reported a position in CLDX in Q1 2019 and held it in 12 quarters. The position peaked at $74K in Q3 2021. 168 funds tracked by Wall St. Rank hold CLDX as of Q1 2022.

Geneos Wealth Management reported no remaining Celldex Therapeutics position as of Q1 2022 after selling out during the quarter.
Geneos Wealth Management sold 1,333 Celldex Therapeutics shares in Q1 2022, an estimated $51K.
Geneos Wealth Management first reported a position in Celldex Therapeutics in Q1 2019 and held it in 12 quarters.
Geneos Wealth Management's Celldex Therapeutics position peaked at $74K in Q3 2021.
168 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2022.

Based on Geneos Wealth Management's 13F filing for Q1 2022, filed 16 May 2022.